In current clinical practice care of diseased patients is often restricted to separated disciplines. However, 25 such an organ-centered approach is not always suitable. For example, cognitive dysfunction is a severe 26 burden in heart failure patients. Moreover, these patients have an increased risk for age-associated 27 dementias. The underlying molecular mechanisms are presently unknown and thus corresponding 28 therapeutic strategies to improve cognition in heart failure patients are missing. Using mice as model 29 organisms we show that heart failure leads to specific changes in hippocampal gene-expression, a brain 30 region intimately linked to cognition. These changes reflect increased cellular stress pathways which 31 eventually lead to loss of neuronal euchromatin and reduced expression of a hippocampal gene cluster 32 essential for cognition. Consequently, mice suffering from heart failure exhibit impaired memory 33 function. These pathological changes are ameliorated via the administration of a drug that promotes 34 neuronal euchromatin formation. Our study provides first insight to the molecular processes by which 35 heart failure contributes to neuronal dysfunction and point to novel therapeutic avenues to treat cognitive 36 defects in heart failure patients. 37 38 39 40 41 2 1 2 3 1 Results 2 3 Heart failure in CamkIIδc TG mice leads to hippocampal gene expression changes indicative of 4 dementia 5
Introduction

4
Traditionally, clinical medicine is organized by organ-centered disciplines which is reflected in the 5 currently applied diagnostics and treatments of patients. This approach has been also commonly adopted 6 in research strategies but it is becoming evident that novel interdisciplinary efforts are needed to improve 5 into account that impaired expression of genes essential for cognitive function is also a key hallmark of 1 dementia, these data provide a plausible hypothesis to explain -at least in partcognitive dysfunction in 2 response to HF. To provide further evidence for this hypothesis, we first retrieved published datasets in 3 which brain-specific gene-expression changes were reported in mouse models with impaired memory 4 function, namely models for aging-associated memory decline (Benito, Urbanke et al., 2015) , models for 5 AD (Gjoneska, Pfenning et al., 2015) and Fronto-temporal dementia (FTLD) (Swarup, Hinz et al., 2018) . 6 We compared these datasets to the transcriptional alterations observed in the hippocampus of CamkIIδc 7 TG mice ( Fig 1J) . Interestingly, there was a significant overlap of genes up-regulated in the hippocampus 8 of CamkIIδc TG mice and genes up-regulated in the hippocampus of cognitively impaired old mice, in 9 CK-p25 mice representing a model for AD-like neurodegeneration and in the cortex of FVB mice, 10 representing a mouse model for fronto-temporal dementia FTLD (Fig 1J) . Similarly, genes down-11 regulated in the hippocampus of CamkIIδc TG mice significantly overlapped with the genes down-12 regulated in models for aging, AD-like neurodegeneration and FTLD (Fig 1J) .
13
Thus, the hippocampal gene-expression signature observed in response to heart failure partly overlaps to 14 the gene-expression changes detected in cognitive diseases. On this basis we hypothesized that aberrant 15 hippocampal gene-expression and especially the decreased expression of learning and memory genes 16 could be a central process in heart failure mediated cognitive impairment and might therefore represent a 17 suitable target for therapeutic intervention. To further substantialize and test this hypothesis, we first 18 decided to first analyze memory function in CamkIIδc TG mice directly. 19 20 Heart failure in CamkIIδc TG is associated with impaired hippocampus-dependent memory 21 consolidation. 22 Three-month-old CamkIIδc TG (n=16) and control mice (n=13) were subjected to behavioral testing.
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Importantly, when subjected to the open field test, CamkIIδc TG and control mice traveled similar 24 distances with the same speed, indicating that explorative behavior and basal motor-function is normal in 25 CamkIIδc TG mice (Fig 2A) . Both groups also spent similar time in the center of the open field arena,
26
suggesting that anxiety behavior is not affected in CamkIIδc TG mice (Fig 2A) . Subsequently, mice were 27 subjected to the Barnes Maze, a hippocampus-dependent spatial navigation-learning test (see methods for 28 details). Two-way ANOVA analysis revealed that CamkIIδc TG mice spent significantly more time to 29 find the escape hole when compared to littermate controls ( Fig 2B) . These data suggest that 30 hippocampus-dependent memory function is impaired in CamkIIδc TG mice. A detailed analysis of the 31 different strategies to find the escape hole confirmed this observation and revealed that in comparison to 32 control mice, CamkIIδc TG mice failed to adapt hippocampus-dependent strategies (direct, short and long 33 chaining approaches), which are generally considered to depend on higher cognitive abilities than the 34 6 other strategies (Fig. 2C) . To quantify this observation, we calculated the cumulative strategy score (see 1 methods for details) that was significantly reduced in CamkIIδc TG mice when compared to the control 2 group (Fig 2D) , further confirming that CamkIIδc TG mice exhibit impaired hippocampus-dependent 3 learning abilities. We also assayed memory retrieval 24h after the final day of training by placing the 4 mice into the Barnes Maze arena with the escape hole being closed and measured the visits to the escape 5 hole. The number of visits to the escape hole during the 120 sec test period was significantly lower in 6 CamkIIδc TG mice when compared to the control group, indicating impaired retrieval of spatial memories 7 ( Fig 2E) . In summary, these findings are in line with our gene-expression data (See Fig. 1 ) and show that 8 CamkIIδc overexpression-induced heart failure leads to cognitive deficits. The finding that CamkIIδc mice indeed exhibit memory impairments allowed us to move on and explore 13 our hypothesis that decreased expression of hippocampal learning and memory genes might be one of the 14 underlying mechanisms by which heart failure leads to cognitive decline. Our gene-expression data 15 suggest that genes down-regulated in the hippocampal CA1 region of CamkIIδc TG mice mainly reflect 16 neuron-specific changes (See Figure 1F ). In addition to pathways related to "cognition", a major 17 molecular process linked to these genes was protein methylation including down-regulation of H3K4-18 methlytransferases such as Kmt2a (see Fig 1H) . Since reduced neuronal expression of Kmt2a and 19 corresponding genome-wide reduction of H3K4me3 has been linked to memory impairment and AD 20 (Gjoneska et al., 2015) (Kerimoglu et al., 2017) , these data point to the possibility that altered H3K4-21 methylation mayat least in part -underlie the observed down-regulation of neuronal genes in CamkIIδc
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TG mice. To test this hypothesis, we retrieved and re-analyzed hippocampal RNA-seq data from mutant 23 mice that lack the H3K4-methyltransferases Kmt2a or Kmt2b from hippocampal neurons of the adult 24 brain and also display hippocampus-dependent memory impairment (Kerimoglu et al., 2013) (Kerimoglu 25 et al., 2017) . Our data reveal that genes decreased in CamkIIδc TG mice show a significant overlap with 26 the genes affected in Kmt2a mutant mice ( Fig 3A) . In contrast, no significant overlap was seen when 27 genes affected in CamkIIδc TG and Kmt2b mice were compared ( Fig 3A) . These findings are in line with 28 the observation that Kmt2a but not Kmt2b is reduced in CamkIIδc TG mice and further supports the idea 29 that changes in H3K4 methylation may contribute to decreased neuronal gene expression in CamkIIδc TG 30 mice. To test this possibility directly, we decided to measure neuronal H3K4me3 in the hippocampal CA1 31 region of CamkIIδc TG and control mice via chromatin-immunoprecipitation followed by next-generation 32 sequencing (ChIP-seq). Tissue of the hippocampal CA1 region was processed and subjected to FACS to 33 isolate neuronal nuclei using an established protocol ( Fig 3B) (Benito et al., 2015, Halder, Hennion et al., 1 across the entire genome. In line with previous findings from neuronal nuclei (Kerimoglu et al., 2017 ) and 2 other tissues, the transcription start site (TSS) of genes was the major regulatory region where these peaks 3 were localized ( Fig 3C) . When we compared H3K4me3 at the TSS of CamkIIδc TG and control mice we 4 observed 4627 genes with decreased and 609 genes with significantly increased H3K4me3 peaks at the 5 TSS ( Fig 3D) . It is important to reiterate that the ChIP-seq data stems specifically from neuronal nuclei of 6 the hippocampal CA1 region allowing us to test the hypothesis that reduced neuronal H3K4me3 would 7 explain the decreased expression of neuronal genes. Indeed, genes down-regulated in CamkIIδc TG (See 8 Fig 1F, G) showed significantly reduced H3K4me3 level at their TSS ( Fig 3E) . In sum, these data 9 provide strong evidence for the view that reduced neuronal H3K4me3 plays a crucial role in impaired 10 neuronal gene expression observed in CamkIIδc TG mice and thereby contributes to heart failure induced 11 memory loss.
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Reinstating hippocampal gene-expression rescues memory impairment in CamkIIδc TG mice 14
Our findings point to the possibility that therapeutic strategies to increase H3K4me3 may help to 15 ameliorate cognitive impairment in CamkIIδc TG mice and could provide a novel approach to manage 16 cognitive impairments in heart failure patients. H3K4me3 is a chromatin mark linked to active gene-17 expression and euchromatin conformation. Histone-deacetylase (HDAC) inhibitors increase histone-18 acetylation and thereby favor euchromatin formation. Moreover, administration of HDAC inhibitors 19 could reinstate memory function in various mouse models of neurodegenerative diseases (Fischer, 2014b) 20 and the HDAC inhibitor Vorinostat is currently tested as therapeutic intervention in AD patients
21
(https://clinicaltrials.gov/ct2/show/NCT03056495). Notably, HDAC inhibitors were also found to 22 reinstate hippocampal H3K4me3 and improve spatial reference learning in mice that lack the histone-23 metyhltransferase Kmt2d (Bjornsson, Benjamin et al., 2014) . On this basis we hypothesized that 24 administration of Vorinostat might help to reinstate memory function in CamkIIδc TG mice, which would 25 also provide further causal evidence for the role of altered neuronal gene-expression in HF-induced 26 memory impairment. In a pilot experiment we found that Vorinostat was able to significantly enhance 27 H3K9 acetylation and H3K4me3 -two euchromatin marks that are functionally related (Kerimoglu et al., 28 2013) (Kerimoglu et al., 2017 , Stilling, Rönicke et al., 2014 Fig 4B) . Moreover, Vorinostat had no effect on 34 8 these parameters. Next, mice were subjected to the Barnes Maze paradigm to evaluate spatial reference 1 memory. Consistent with our previous observation, vehicle treated mice displayed impaired learning 2 behavior when compared to the corresponding wild-type group (Fig 4C) . In contrast, CamkIIδc TG mice 3 treated with Vorinostat were able to master the Barnes Maze task similar to the wild type control group 4 ( Fig 4C) . Essentially, the escape latency in Vorinostat-treated CamkIIδc TG and wild-type control groups 5 was not significantly different, suggesting that Vorinostat administration reinstates hippocampus-6 dependent memory function in CamkIIδc TG mice ( Fig 4C) . A more detailed analysis of the training 7 procedure revealed that similar to wild type mice, Vorinostat-treated CamkIIδc TG mice eventually adopt 8 cognitive strategies such as direct, short and long chaining strategies, while vehicle-treated CamkIIδc TG 9 failed to do so ( Fig 4D) . Consistently, the cumulative cognitive score that was calculated based on these 10 strategies (see methods for details) revealed a significant impairment of vehicle-treated CamkIIδc TG 11 mice, when compared to the wild-type control group, while no such difference was observed for
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Vorinostat-treated CamkIIδc TG ( Fig 4E) . A similar observation was made when mice were subjected to 13 the memory test after 7 training trials ( Fig 4F) . These data show that oral administration of Vorinostat 14 ameliorates memory impairment in CamkIIδc TG mice.
16
Vorinostat ameliorates gene-expression changes in CamkIIδc TG mice 17
Vorinostat treatment of CamkIIδc TG mice had no significant effect on cardiac pathology (Expanded 18 View Fig 2) suggesting that reinstatement of memory function in our experimental system is most likely 19 linked to brain-specific processes. Thus, we analyzed gene-expression in the hippocampal CA1 region of 20 vehicle-treated wild type mice as well as in vehicle and Vorinostat-treated CamkIIδc TG mice via RNA-21 seq ( Fig 5A) . In line with our previous observation (See Fig 1D-G) , RNA-seq data analysis revealed a 22 major deregulation of gene-expression in vehicle-treated CamkIIδc TG mice compared to the vehicle-23 treated wild-type control group (Expanded View Fig 3A, B) . Our further analysis shows that Vorinostat 24 could partially restore physiological gene-expression in CamkIIδc TG mice (Expanded View Fig 3B, C) .
25
The finding that Vorinostat-treatment increases the expression of genes that were down-regulated in
26
CamkIIδc TG mice can easily be explained by the effect of Vorinostat on euchromatin formation.
27
However, the observation that Vorinostat also decreases the expression of genes that were elevated in 28 CamkIIδc TG mice is most likely due to additional mechanisms.
29
To further elucidate this, we decided to investigate the RNAseq data in greater detail. Recent studies 30 showed that the detection of regulatory co-expression modules is a suitable approach to further 31 understand transcriptional plasticity in health and disease (Gandal, Zhang et al., 2018) . To this end we 32 performed Weighted Gene Co-expression Analysis (Langfelder & Horvath, 2008) ( Fig 5B) and identified 33 14 different modules in the entire RNA-seq dataset (see methods for details). Two of these modules -34 9 namely RNA module 1 and 2 -exhibited significantly different expression amongst vehicle-treated 1 CamkIIδc TG and wild-type control mice. RNA module 1 was decreased in vehicle-treated CamkIIδc TG 2 mice, while its expression was partially rescued upon Vorinostat treatment ( Fig 5C) . Gene ontology 3 analysis suggested that the genes of RNA module 1 are linked to cognition, learning and memory ( Fig   4   5C ). Further analysis identified a cluster of 30 hub genes within module 1. Notably, 26 of genes were 5 shown to cause to memory impairment when their expression was manipultated (Fig 5D; supplemental 6 table 4). In contrast, RNA module 2 was significantly increased in vehicle-treated CamkIIδc TG mice 7 when compared to the vehicle-treated wild-type control group (Fig 5E) . Expression of this cluster was 8 partially deceased to control levels in Vorinostat-treated CamkIIδc TG mice ( Fig 5E) . In line with our 9 previous analysis of up-regulated genes, the genes of RNA module 2 were mainly linked to cellular 10 stress-related pathways (Fig 5E) . In line with our previous findings the genes of RNA module 2 showed a 11 significant overlap to genes increased in response to hypoxia in neuronal cultures (this study), human 12 brain organoids exposed to hypoxia (Pașca, Park et al.) or ER-stress while the genes of the cognition-13 related RNA module 2 were decreased under the same conditions (Expanded View Fig 4) .
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The question remained how Vorinostat, an epigenetic drug that is linked to euchromatin formation and the 15 activation of gene expression, would decrease the observed pathological gene-expression response linked 16 to hypoxia and cellular stress pathways. One possible explanation is that Vorinostat induces molecular 17 processes that antagonize this type of pathological gene expression. MicroRNAs are small non-coding
18
RNAs that regulate cellular homeostasis via binding to a target mRNA thereby causing its degradation or 19 inhibition of translation (Gurtan & Sharp, 2013) . Compensatory microRNA responses have been 20 described in response to various cellular stress conditions (Kagias, Nehammer et al., 2012) Fig 5G) , while its expression was increased to physiological levels upon Vorinostat-treatment ( Fig 5G) .
31
Next, we asked whether the increased expression of microRNA module 2 would be correlated to the 32 corresponding expression of stress-response genes increased in the hippocampal CA1 region of CamkIIδc 33 TG mice. To this end we first performed a pairwise correlation analysis between genes and microRNAs that were differentially expressed in Vorinostat-treated vs. vehicle-treated CamkIIδc TG mice. We 1 observed that microRNAs within microRNA module 2 showed a significant negative correlation to the 2 hub genes of RNA module 2, representing the module linked to cellular stress responses and autophagy 3 ( Fig 5H) . These data suggest that Vorinostat-treatment in CamkIIδc TG mice increases the expression of 4 microRNAs that antagonize the expression of genes linked to pathological cellular stress. Further 5 evidence for this view stems from the finding that these microRNAs are mainly encoded within genes that 6 exhibit reduced hippocampal H3K4me3 in CamkIIδc TG mice (Expanded View Fig 5, C) .
7
In sum these data suggest that aberrant neuronal gene expression plays a central role in heart failure 8 associated cognitive decline. In turn, approaches that target these gene-expression changes could provide 9 a novel therapeutic avenue to manage cognitive dysfunction in heart failure patients.
11
Discussion
12
Employing a genetic mouse model for HF, we show for the first time that HF leads to substantial changes 13 in hippocampal gene expression. The genes that were up-regulated significantly overlap with genes 14 deregulated in neurons exposed to cellular stress such as oxidative and ER stress. These data suggest that 15 cardiac dysfunction, which has been linked to reduced blood flow to the brain (Bikkina et al., 1994, 16 Verdecchia et al., 2001) , initiates a cellular stress response that eventually manifest at the level of neural 17 gene-expression. Our results also reveal that these hippocampal gene-expression changes in mice 18 suffering from HF parallel the changes observed in models for neurodegenerative diseases (Benito et al., 19 2015) (Gjoneska et al., 2015) (Gispert, Brehm et al., 2015) (Swarup et al., 2018) . This is in line with previous 20 reports suggesting that hypoxia-mediated oxidative and ER-stress are early and common events in 21 neurodegenerative diseases that can trigger subsequent pathological changes associated with memory loss 22 (Feldstein, 2012) (Xiang, Wang et al., 2017) (Butterfield & Halliwell, 2019) . Indeed, further analysis of 23 the data revealed that the hippocampal genes down-regulated in response to heart failure represent cellular 24 processes linked to cognition and are similar to the gene-expression changes observed in models for 25 dementia. These findings suggest that activation of cellular stress pathways might be one reason for the 26 down-regulation of hippocampal genes essential for cognition. Support for this view stems from our 27 observation that the sole exposure of neuronal cultures to hypoxia or ER-stress leads to the down-28 regulation of such neuronal gene-sets. In line with these gene-expression data we show that CamkIIδc TG 29 mice exhibit impaired hippocampus-dependent learning and memory. Although our report of memory 30 impairment in a heart failure mouse model is novel, these data are in agreement with various studies in 31 humans showing that cardiac dysfunction is associated with cognitive decline and an increased dementia 1 remained poorly understood so far (e.g. see (Patel, Moalem et al., 2017) ). How precisely activation of the 2 various cellular stress pathways leads to the down-regulation of genes essential for cognition remains to 3 be investigated and is likely to be multifactorial making it difficult to identify suitable targets for 4 therapeutic intervention. From a therapeutic point of view, the fact that hippocampal genes linked to 5 cognition are eventually decreased, might offer a more promising avenue to treat cognitive defects in HF 6 patients, especially since these patients usually already suffer from the disease for a prolonged time 7 period. In this context, it is important to reiterate that our data suggest that HF eventually leads to the 8 down-regulation of gene-clusters important for cognition via processes linked to reduced histone-9 methylation, especially deceased levels of the euchromatin mark H3K4me3. These findings are in line 10 with current literature showing that proper neuronal H3K4me3 is essential for memory consolidation 11 (Gupta et al., 2010 , Kerimoglu et al., 2013 (Jakovcevski et al., 2015) (Kerimoglu et al., 2017) . Our data hint 12 at a specific role of the H3K4 methyltransferase Kmt2a, which is down-regulated in the hippocampus of 13 CamkIIδc TG mice. These findings are in line with recent reports showing that mice lacking Kmt2A in 14 excitatory neurons of the hippocampus exhibit impaired learning and memory and decreased expression 15 of genes implicated in cognitive function (Kerimoglu et al., 2017) . Indeed, our data show that genes 16 deregulated in the hippocampi of Kmt2a knock out mice -but not of Kmt2b -significantly overlap with 17 deregulated genes in CamkIIδc TG mice. Taken together, these data point to a scenario in which heart 18 failure leads to hypoxia and cellular stress, eventually driving loss of neuronal euchromatin causing 19 decreased expression of neuronal plasticity genes essential for cognition ( Fig 6) . Further support for this 20 view stems from our data that administration of an epigenetic drugs that promotes euchromatin formation 21 reinstates memory in CamkIIδc TG mice and that this effect cannot be simply explained by improved 22 cardiac output. These findings pave the road to a novel therapeutic approach to treat HF-induced 23 cognitive dysfunction and lower the risk for age-associated dementia in these patients. To this end,
24
although cerebral hypoperfusion and cellular stress appear to be initial events in the development of 25 cognitive decline in patients suffering for cardiac dysfunction, our data suggest that they eventually lead 26 to epigenetic changes of histone methylation in neurons. Such epigenetic alterations are known to 27 represent long-term adaptive changes that can persist even in the absence of the initial stimulus (Fischer, 28 2014a). Thus, targeting the epigenome has emerged as a promising therapeutic option to treat complex 29 and multifactorial diseases including dementia, even at an advanced stage of the disease (Fischer, 2014b) 30 (Fischer, 2014a) . In fact, previous studies showed that other risk factors for dementia such as aging 31 (Peleg, Sananbenesi et al., 2010) (Benito et al., 2015) , protein aggregation, (Kilgore, Miller et al., 2010) 32 (Govindarajan, Agis-Balboa et al., 2011) (Benito et al., 2015) (Gjoneska et al., 2015) , neuropsychiatric 33 diseases (Nestler, Peña et al., 2015) or peripheral inflammation (Wendeln AC, Häsler LM et al., 2018) 12 lead to similar changes representing a loss of neuronal euchromatin and reduced expression of genes 1 linked to cognition. Of note, therapeutic strategies to reinstate euchromatin related gene-expression were 2 able to improve memory function in such models (Benito et al., 2015) (Bahari-Javan, Varbanov et al., 3 2017). For example, inhibitors of histone deacetylases (HDAC) have emerged as promising candidates to 4 treat cognitive decline, and the FDA approved HDAC inhibitor Vorinostat is currently undergoing trials 5 in Alzheimer's disease patients (ClinicalTrials.gov Identifier: NCT03056495). As mentioned above, oral 6 administration of Vorinostat to CamkIIδc TG mice improved their learning and memory abilities. These 7 findings cannot be explained by improved cardiac function, since a one-month treatment of CamkIIδc TG 8 mice with Vorinostat had no significant effect on heart failure. However, Vorinostat treatment increased 9 the expression of formerly downregulated hippocampal genes linked to cognition. In fact, our detailed 10 analyses revealed that Vorinostat reinstated the expression of a specific gene cluster in which nearly every 11 hub-gene was shown to be essential for memory function. Hence, reducing either of these genes alone 12 was found to cause memory impairment (see supplemental table 3). While these findings are in line with 13 the know role of Vorinostat to induced euchormatin and gene-expression, it was surprising to see that
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Vorinostat treated CamkIIδc TG also exhibited reduced expression of genes linked to cellular stress 15 responses. Our data suggest that this effect is mediated via the induction of a compensatory microRNA 16 network that downregulated cellular stress response hub genes (Fig 6) . These findings are in line with the 17 reported role of the microRNAome as one key molecular process to maintain cellular homeostasis and 18 reports that link microRNA expression to compensatory mechanisms in various diseases (Gebert & 19 MacRae, 2019) . We cannot exclude the possibility that the improved memory function in response to 20 Vorinostat-treatment is mediated by other mechanisms. For example, Vorinsotat also acts on non-histone 21 proteins and has been found to suppress hypoxia signaling in cancer models (Zhang, Yang et al., 2017) .
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Moreover, although Vorinostat increases H3K4me3, this indirect effect is most likely mediated by 23 increased histone acetylation that generally promotes euchromatin formation. In line with this previous 24 findings show that Kmts act in concert with histone-acetyltransferases (Kerimoglu et al., 2013) 25 (Kerimoglu et al., 2017) (Husmann & Gozani, 2019) . Nevertheless, in the future, it will be important to 26 investigate whether therapeutic approaches that target more directly H3K4me3 are even more efficient to 27 reinstate memory function in response to HF.
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In conclusion, our data elucidate the molecular mechanisms by which cardiac dysfunction contributes to 29 cognitive impairment and suggest a key role for epigenetic neuronal gene expression. Targeting gene 30 expression changes in the brain, through drugs such as HDAC inhibitor Vorinostat, ameliorate memory 31 impairment and partially reinstate physiological gene expression. Thus, therapeutic strategies that target 32 epigenetic gene expression may be a suitable approach to treat cognitive dysfunction even in chronic 33 heart failure patients and lower their risk of developing age-associated cognitive diseases such as AD. Chromatin immunoprecipitation was performed according to (Halder et al., 2016) Primary hippocampal neuronal culture was prepared as described previous (Benito et al., 2015) 12
Experiments were performed at DIV 10. Endoplasmic reticulum stress was induced in primary 13 hippocampal neurons using Tunicamycin (Sigma Aldrich). 2ug/mL of Tunicamycin was added to primary Heart failure and a reduced ejection fraction lead to cerebral hypoperfusion which is in line with a hippocampal gene-expression response linked to oxidative and ER-stress. Our data suggest that oxidative and ER-stress drive reduced expression of genes important for memory function which involves reduced neuronal H3K4me3 representation loss of euchromatin. Administration of the HDAC inhibitor Vorinostat partially increases the expression of memory-related genes but also decreases the expression of genes linked to oxidative and ER-stress via the induction of a microRNA cluster. Fig 4. Hypogeometric overlap analysis comparing conserved the gene-expression networks RNA module 1 and 2 to hypoxic and ER stress conditions Heatmaps summarizing results from hypergeometric tests for genes in RNA module 1 and 2 with stress conditions in di erent experimental settings. Hypoxia (1% O2, 4h) and endoplasmic stress (tunicamycin 2 ug/mL, 6h) was modeled in primary hippocampal neurons. Gene expression data on hypoxia from human brain organoid data is retrieved from 
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